Acadia Healthcare Company Inc Dossier - Source-backed chat

Acadia Healthcare Company Inc

ACHCNASDAQ

SectorHealth Care

IndustryMedical Care Facilities

Beta (adjusted)0.74

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $27.50Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.6B

Enterprise Value $4.9B

Shares Outstanding 89.5M diluted

Moat Rating None

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Acadia Healthcare presents a classic tension between robust long-term demand for behavioral health services and near-term execution headwinds. While the company continues to deliver solid top-line growth driven by same-facility volume expansion and strategic joint-venture bed additions, its financial performance remains heavily pressured by elevated professional and general liability (PLGL) expenses, legal settlements, and payor authorization scrutiny. Management's decision to reduce capital expenditures in 2026 is expected to stabilize cash flows and support a positive free cash flow inflection, but near-term margin erosion and leverage concerns warrant a cautious stance until cleaner operational execution is demonstrated.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$14.50

Mean target$33.39

High · most bullish analyst$41.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$14.5020%

The bear case centers on a prolonged margin squeeze driven by persistent labor shortages, high wage inflation, and escalating legal liabilities. If the company faces further 'nuclear' verdicts or substantial settlement charges related to ongoing class-action lawsuits, its net leverage ratio could rise above the guided 4.4x to 4.5x range, triggering credit rating downgrades and restricting capital allocation flexibility. Additionally, continued payor scrutiny and Medicaid volume softness could further depress acute care margins.

Base CaseCentral scenario

$33.3950%

Matches the consensus mean

The base case assumes Acadia successfully delivers on its revised full-year 2026 guidance, with revenue reaching $3.37 billion to $3.45 billion and Adjusted EBITDA stabilizing between $580 million and $615 million. Same-facility growth is expected to remain steady, supported by the ramp-up of newly added beds, while labor cost pressures and PLGL expenses are gradually contained. The stock is likely to trade in line with its peer group as the market monitors the stabilization of operating margins.

Bull CaseUpside scenario

$41.0030%

The bull case is built on a successful operational turnaround and a positive free cash flow inflection in 2026. By slashing capital expenditures to approximately $300 million, Acadia is positioned to generate positive free cash flow for the first time in years, which can be utilized to reduce debt or execute share repurchases. Furthermore, activist pressure from Engine Capital could catalyze a strategic review or governance improvements, leading to a significant re-rating of the stock toward historical multiples.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong secular tailwinds driven by rising national demand for mental health and substance abuse treatment.
Market leadership as the largest standalone behavioral healthcare provider in the United States with a highly diversified facility footprint.
Expected positive free cash flow inflection in 2026 driven by disciplined capital expenditure cuts.
Strategic joint-venture partnerships with major health systems that accelerate bed expansion and referral pipelines.

Key Investment Risks

Elevated professional liability and general liability (PLGL) expenses and ongoing class-action litigation risks.
Staffing constraints and clinician wage inflation that pressure operating margins.
Payor authorization headwinds and Medicaid reimbursement policy changes that impact patient volumes.
High leverage levels with net leverage expected to temporarily rise to 4.4x-4.5x in the near term.

Thesis Invalidation Triggers

Full-year 2026 Adjusted EBITDA falling below the lower bound of the guided $580 million range.
Net leverage ratio failing to return to the targeted 3.9x to 4.2x range by year-end 2026.
An unexpected multi-million dollar legal settlement or adverse jury verdict that severely impacts cash reserves.
A material decline in same-facility admissions or patient day growth over consecutive quarters.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.